Liposomal Amphotericin B Therapy

Introduction to Liposomal Amphotericin B

Liposomal amphotericin B represents a critical advancement over conventional amphotericin B deoxycholate, offering dramatically reduced nephrotoxicity while maintaining equivalent antifungal efficacy, making it the preferred formulation for immunocompromised patients, particularly those with pre-existing renal impairment or at high risk for kidney dysfunction 1, 2

Lipid formulations demonstrate significantly decreased nephrotoxicity and infusion reactions compared to conventional amphotericin B deoxycholate 3, 4
Conventional amphotericin B at higher doses causes severe secondary effects including infusion reactions, nephrotoxicity, and metabolic disorders, whereas lipid formulations avoid these complications 3, 5
Approximately 19-50% of patients still experience some degree of renal injury with liposomal formulation, but adverse events remain manageable with only 12% requiring readmission 2

Both formulations are equally effective when used at appropriate dosages for invasive fungal infections 1
In patients with disseminated histoplasmosis and AIDS, liposomal amphotericin B achieved 88% response rate versus 64% with conventional formulation, with significantly lower mortality (2% vs 13%) 6

Conventional amphotericin B deoxycholate: 0.6–1.0 mg/kg per day 1
Liposomal amphotericin B: 3–5 mg/kg per day 1
The higher dosing for lipid formulations is necessary to achieve equivalent tissue concentrations due to altered pharmacokinetics 1
Nebulized liposomal amphotericin B for lung transplant recipients: 25 mg three times weekly, avoiding systemic absorption and side effects 7, 5
Parenteral amphotericin B lipid formulation for high-risk solid organ transplant patients: 2.5–5 mg/kg/day 7, 3
For liver transplant recipients, liposomal amphotericin B at 1 mg/kg/day for 5–10 days reduces invasive mycoses 3, 4

High-risk patients for early invasive fungal infection include those requiring renal clearance techniques, CMV disease, acute liver failure, primary graft failure, or re-transplantation 7, 3
Duration of therapy is determined by presence of risk factors rather than fixed duration 7, 3
For moderate to severe disseminated histoplasmosis in AIDS patients, liposomal amphotericin B is significantly more effective than conventional formulation 6

Hydration with 0.9% saline intravenously 30 minutes before infusion ameliorates nephrotoxicity 1, 2
Monitor serum creatinine and electrolytes at minimum once or twice weekly 1, 2
Use the lowest effective dose and shortest duration of therapy 1, 2
Pre-existing renal impairment is not an absolute contraindication to liposomal amphotericin B, unlike conventional formulation 8
Neither dialysis nor hemofiltration significantly reduces amphotericin B serum concentrations, so dose adjustment for renal replacement therapy is not required 2
High doses above 5 mg/kg/day significantly increase renal toxicity risk; the AmBiLoad trial showed no efficacy benefit for 10 mg/kg/day versus 3 mg/kg/day, with worse tolerability at higher doses 2
Anticalcineurin drugs (cyclosporine, tacrolimus) require close concentration monitoring due to potential interactions 7, 3

Do not use conventional amphotericin B deoxycholate in patients with pre-existing renal disease—lipid formulations are mandatory in this population 3, 4, 1